Brian Park, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Cardiovascular and Metabolic Disorders

Semaglutide Increases Weight Loss When Added to Behavioral Therapy

Brian Park, PharmD

November 12, 2020

The 68-week STEP 3 trial compared the efficacy and safety of semaglutide, a glucagon-like peptide 1 receptor agonist, to placebo plus IBT.

Cardiovascular and Metabolic Disorders

Empagliflozin Fast Tracked for Improving Outcomes Following Myocardial Infarction

Brian Park, PharmD

September 22, 2020

The effect of empagliflozin on all-cause mortality and hospitalization for heart failure will be evaluated in the in phase 3 EMPACT-MI study.

Cardiovascular and Metabolic Disorders

Evolocumab Reduces LDL-C in Pediatric Heterozygous FH

Brian Park, PharmD

September 8, 2020

The multicenter, double-blind, placebo-controlled HAUSER-RCT study assessed the efficacy and safety of evolocumab in 157 patients aged 10 to 17 years with HeFH.

Diabetes

Boxed Warning Removed From Canagliflozin Labeling

Brian Park, PharmD

August 28, 2020

The FDA concluded “the risk no longer meets the standard for a Boxed Warning.”

Diabetes

Autonomous AI System Cleared for Diabetic Retinopathy Screening

Brian Park, PharmD

August 18, 2020

EyeArt is the first FDA-cleared AI technology for autonomous detection of more than mild diabetic retinopathy and vision-threatening diabetic retinopathy.

Diabetes

Capsaicin Patch Approved for Painful Diabetic Peripheral Neuropathy of the Feet

Brian Park, PharmD

August 11, 2020

The FDA has approved Qutenza® (capsaicin 8% patch; Averitas Pharma) for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet.

Diabetes

Ready-to-Use Glucagon Pen Now Available for Severe Hypoglycemia

Brian Park, PharmD

July 7, 2020

Xeris Pharmaceuticals announced the launch of Gvoke HypoPen™ (glucagon) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and older.

Diabetes

FDA Approves Metoclopramide Nasal Spray for Diabetic Gastroparesis

Brian Park, PharmD

June 29, 2020

The FDA has approved Gimoti™ (metoclopramide; Evoke Pharma) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

Diabetes

New Rapid-Acting Insulin Lispro Approved by FDA

Brian Park, PharmD

June 19, 2020

The FDA has approved Lyumjev™ (insulin lispro-aabc injection; Lilly) to improve glycemic control in adults with type 1 and type 2 diabetes.

Diabetes

FDA Approves Long-Acting Insulin Glargine Injection for T1D, T2D

Brian Park, PharmD

June 19, 2020

The FDA has approved Semglee™ (insulin glargine injection; Mylan and Biocon) to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Next post in Diabetes